Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2011

01-01-2011 | Original Article

Effectiveness of the Immunofecal Occult Blood Test for Colorectal Cancer Screening in a Large Population

Authors: Haiyun Yang, Zhizheng Ge, Jun Dai, Xiaobo Li, Yunjie Gao

Published in: Digestive Diseases and Sciences | Issue 1/2011

Login to get access

Abstract

Background

Guaiac tests are the most widely used tests to detect colorectal cancer (CRC). However, their sensitivity is relatively low and results may be affected by various factors. Immunofecal occult blood test (IFOBT) is specific for human hemoglobin and does not require dietary restrictions.

Aims

The aim of this study was to evaluate the effectiveness of IFOBT for the screening of precancerous lesions and CRC.

Methods

From July 2006 to June 2007, IFOBT was performed on 5,919 adults who received periodic health examinations in our hospital. The positive cases were examined by colonoscopy and a double-contrast barium enema. Diagnosis was confirmed by histopathological analysis.

Results

Positive IFOBT was detected in 314 of 5,919 cases (5.30%). Further examinations were made in 264 IFOBT-positive cases. Of these, 116 cases with colorectal cancer (16 cases) or precancerous lesions (94 cases with colorectal adenomatous polyps and 6 cases with active ulcerative colitis) were detected. The total detection rate of CRC and precancerous lesions was 43.94% (116/264). TNM classification of 16 CRC cases was as follows: TNM I in eight cases (50.00%), TNM II in seven cases (43.75%) and TNM III in one case (6.25%), indicating IFOBT can detect CRC in the early stages.

Conclusion

Regular IFOBT can detect precancerous lesions and CRC in early stages and can thus reduce mortality from CRC.
Literature
1.
go back to reference Daniel L, Joseph J, Robert H, et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–1403.CrossRef Daniel L, Joseph J, Robert H, et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–1403.CrossRef
2.
go back to reference Autier P. Should organised faecal occult blood test screening be established? Ann Oncol. 2002;13(1):57–60.CrossRefPubMed Autier P. Should organised faecal occult blood test screening be established? Ann Oncol. 2002;13(1):57–60.CrossRefPubMed
3.
go back to reference Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol. 2002;13(1):51–56.CrossRefPubMed Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol. 2002;13(1):51–56.CrossRefPubMed
4.
go back to reference Bleiberg H. Hemoccult should no longer be used for the screening of colorectal cancer. Ann Oncol. 2002;13(1):44–46.CrossRefPubMed Bleiberg H. Hemoccult should no longer be used for the screening of colorectal cancer. Ann Oncol. 2002;13(1):44–46.CrossRefPubMed
5.
go back to reference Levi Z, Hazazi R, Rozen P, et al. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23(9):1359–1364.CrossRefPubMed Levi Z, Hazazi R, Rozen P, et al. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23(9):1359–1364.CrossRefPubMed
6.
go back to reference Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23(3):309–313.CrossRefPubMed Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23(3):309–313.CrossRefPubMed
7.
go back to reference Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13(1):71–75.CrossRefPubMed Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13(1):71–75.CrossRefPubMed
8.
go back to reference Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53(1):44–55.CrossRefPubMed Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53(1):44–55.CrossRefPubMed
9.
go back to reference Labianca R, Beretta GD, Mosconi S, et al. Colorectal cancer: screening. Ann Oncol. 2005;16(Suppl 2: ii):127–132. Labianca R, Beretta GD, Mosconi S, et al. Colorectal cancer: screening. Ann Oncol. 2005;16(Suppl 2: ii):127–132.
10.
go back to reference Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52(3):323–326.CrossRef Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52(3):323–326.CrossRef
11.
go back to reference Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–1109.CrossRefPubMed Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–1109.CrossRefPubMed
12.
go back to reference Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota colon cancer control study. N Eng J Med. 1993;328:1365–1371.CrossRef Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota colon cancer control study. N Eng J Med. 1993;328:1365–1371.CrossRef
13.
go back to reference Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal—occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal—occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed
14.
go back to reference Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colon cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colon cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed
15.
go back to reference La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002;13(1):31–34.CrossRefPubMed La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002;13(1):31–34.CrossRefPubMed
16.
go back to reference Yan HY, Ge ZZ. Research status of fecal occult blood test in the early diagnosis of colorectal cancer. Chin J Gastroenterol. 2006;11(6):376–378. Yan HY, Ge ZZ. Research status of fecal occult blood test in the early diagnosis of colorectal cancer. Chin J Gastroenterol. 2006;11(6):376–378.
17.
go back to reference Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002;94(15):1126–1133.PubMed Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002;94(15):1126–1133.PubMed
18.
go back to reference Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422.CrossRefPubMed Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422.CrossRefPubMed
19.
go back to reference Yeazel MW, Church TR, Jones RM, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13(4):654–657. (Erratum in: Cancer Epidemiol Biomarkers Prev. 2004;13(9):1550).PubMed Yeazel MW, Church TR, Jones RM, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13(4):654–657. (Erratum in: Cancer Epidemiol Biomarkers Prev. 2004;13(9):1550).PubMed
20.
go back to reference Scales CD Jr, Fein S, Muir AJ, et al. Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission. J Clin Gastroenterol. 2006;40(10):913–918.CrossRefPubMed Scales CD Jr, Fein S, Muir AJ, et al. Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission. J Clin Gastroenterol. 2006;40(10):913–918.CrossRefPubMed
21.
go back to reference Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.CrossRefPubMed Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.CrossRefPubMed
22.
go back to reference Rex DK, Overhiser AJ, Chen SC. Estimation of impact of American college of radiology recommendations on CT clonograph reporting for resection of high-risk adenoma findings. Am J Gastroenterol. 2009;104:149–153.CrossRefPubMed Rex DK, Overhiser AJ, Chen SC. Estimation of impact of American college of radiology recommendations on CT clonograph reporting for resection of high-risk adenoma findings. Am J Gastroenterol. 2009;104:149–153.CrossRefPubMed
23.
go back to reference Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13(1):47–50.CrossRefPubMed Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13(1):47–50.CrossRefPubMed
24.
go back to reference Mizutani S, Fumitani M, Kaneshiro E, et al. Fundamental evaluation of fully automated fecal occult blood analyzer “OC-SENSORμ”. J Med Pharm Sci. 2002;47(5):769–773. Mizutani S, Fumitani M, Kaneshiro E, et al. Fundamental evaluation of fully automated fecal occult blood analyzer “OC-SENSORμ”. J Med Pharm Sci. 2002;47(5):769–773.
25.
go back to reference Noboru G, Michiko F, Keiko I, et al. Basic study of OC-SENSOR μ, a compact fully automated immunochemistry analyzer for fecal occult blood tests. J Clin Lab Inst Reag. 2002;25(1):57–62. Noboru G, Michiko F, Keiko I, et al. Basic study of OC-SENSOR μ, a compact fully automated immunochemistry analyzer for fecal occult blood tests. J Clin Lab Inst Reag. 2002;25(1):57–62.
26.
go back to reference Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood-screening test. Am J Gastroenterol. 2005;100(11):2519–2525.CrossRefPubMed Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood-screening test. Am J Gastroenterol. 2005;100(11):2519–2525.CrossRefPubMed
27.
go back to reference Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9(3):99–103.CrossRefPubMed Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9(3):99–103.CrossRefPubMed
28.
go back to reference Robert A, Vilma C, Harmon J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2006;56:11–25.CrossRef Robert A, Vilma C, Harmon J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2006;56:11–25.CrossRef
29.
go back to reference Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25 (quiz 49–50).CrossRefPubMed Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25 (quiz 49–50).CrossRefPubMed
30.
go back to reference U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290.
Metadata
Title
Effectiveness of the Immunofecal Occult Blood Test for Colorectal Cancer Screening in a Large Population
Authors
Haiyun Yang
Zhizheng Ge
Jun Dai
Xiaobo Li
Yunjie Gao
Publication date
01-01-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1264-8

Other articles of this Issue 1/2011

Digestive Diseases and Sciences 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.